STRATA Skin Sciences, Inc. (SSKN) EBITDA Margin (2012 - 2025)

STRATA Skin Sciences has disclosed EBITDA Margin across 14 years of filings, most recently posting 5.25% for Q4 2025.

• In Q4 2025, EBITDA Margin rose 5000.0% year-over-year to 5.25%; the TTM figure through Dec 2025 stood at 15.31% (up 1226.0% YoY), while the FY2025 annual figure was 15.31%, up 1226.0% from the prior year.
• EBITDA Margin came in at 5.25% for Q4 2025 at STRATA Skin Sciences, up from 16.93% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 5.25% in Q4 2025 to a low of 44.75% in Q4 2024.
• Average EBITDA Margin over 5 years is 20.38%, with a median of 18.43% recorded in 2022.
• Year-over-year, EBITDA Margin sank 4087 bps in 2023 and jumped 5000 bps in 2025.
• Over 5 years, EBITDA Margin stood at 6.87% in 2021, then jumped by 118 bps to 1.26% in 2022, then tumbled by 3233 bps to 39.6% in 2023, then decreased by 13 bps to 44.75% in 2024, then jumped by 112 bps to 5.25% in 2025.
• Per Business Quant data, the three most recent EBITDA Margin figures were 5.25% in Q4 2025, 16.93% in Q3 2025, and 30.14% in Q2 2025.